The shares are listed on the HKEX
Davis Polk advised the underwriters in connection with Visen Pharmaceutical’s initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Rule 144A / Regulation S. The gross proceeds from the offering were approximately HK$783.3 million prior to the exercise of the over-allotment option.
Visen Pharmaceutical is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China (including Hong Kong, Macau and Taiwan). Visen Pharmaceutical’s Core Product, lonapegsomatropin, is the only long-acting growth hormone that has demonstrated superior efficacy and comparable safety in active-controlled and parallel-group trial comparisons with daily human growth hormone, as validated in the completed Phase 3 pivotal trial in China.
The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel Wendy Kan, registered foreign lawyer Raymond Lai and associate Jamie Lai. Counsel Alon Gurfinkel and associates Kelli A. Rivers and Ya Sheng Lin provided tax advice. Members of the Davis Polk team are based in the Hong Kong, Beijing and London offices.
The announcement above is not an offer of securities for sale in the United States. The securities referred to herein have not been registered under the U.S. Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an exemption from registration under the Securities Act. The issuer does not intend to register any part of the offering in the United States or to conduct a public offering of the securities in the United States.
____________________________________________
Davis Polk refers to Davis Polk & Wardwell LLP,
a New York limited liability partnership, and its associated entities.
A “partner” may be a member of any of those entities.
__________________________________________________
If you have any questions regarding this deal announcement, please
contact Wing Lai at (852) 2533 3348 or wing.lai@davispolk.com
or Maggie Wong at (852) 2533 1005 or maggie.wong@davispolk.com
Davis Polk (www.davispolk.com) is among the world’s leading law firms across our entire practice. This excellence and breadth has made us the firm of choice for many of the world’s leading companies and financial institutions as they address the diverse legal and business challenges they face.
About Davis Polk’s Asia Practice. Our Asia practice includes extensive experience in securities offerings, cross-border mergers and acquisitions, privatizations, joint ventures, project financings, other bank financings and other transactions involving Asia and the Pacific Rim, as well as commercial litigation, bank regulatory matters and questions of U.S. and international tax law. Davis Polk has a renowned capital markets practice and are regularly ranked as a leading law firm for equity and debt capital markets work in Asia. Davis Polk has been active in Asia since working with J.P. Morgan & Co. on railroad financings in China and on financings for the reconstruction of Tokyo since the early 1900s. We are one of the first Wall Street firms to open offices in Tokyo and Hong Kong, and later opened Beijing office.
Davis Polk’s Hong Kong office, opened in 1993 and was one of the first offices opened by a major Wall Street firm in Hong Kong. For more than three decades, we have been involved in many of the region’s most important and high profile capital markets and M&A/private equity transactions, as well as litigation matters in China and elsewhere in Asia. Our world-class global enforcement and litigation practice is one of the largest in the Asian market. The firm’s sophisticated Asia practice and our fully integrated international practices provide our clients with one of the most efficient full-service global law firms in Asia today.
Our Beijing office, which opened in early 2007, joins Hong Kong and Tokyo as the firm’s third location in Asia, and expands the presence and reach of Davis Polk’s broad and highly successful practice in China.
Our Tokyo office, which opened in 1987, is our first Asia office and the base for our Japan practice. Tokyo office lawyers not qualified as Gaikokuho Jimu Bengoshi are qualified under the laws of New York or other jurisdictions outside of Japan and working in Japan under the supervision and direction of Gaikokuho Jimu Bengoshi resident in the firm’s Tokyo office.
